Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
Cancer Immunology, Immunotherapy : CII|September 13, 2021
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodiesMorinobu Seki, Shigehisa Kitano, Shigeaki Suzuki
Biomed Research International|July 11, 2015
Clinical Development of Immune Checkpoint InhibitorsAyumu Ito, Shunsuke Kondo, Kohei Tada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[The Analysis of Tumor Immune Microenvironment in Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy]Daiki Ikarashi, Shigehisa Kitano, Tetsuya Nakatsura, et al.
BMC Cancer|October 31, 2019
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reportsKoji Yoshino, Takayuki Nakayama, Ayumu Ito, et al.
Lancet (London, England)|July 4, 2021
Pembrolizumab plus chemotherapy in triple-negative breast cancerJun Masuda, Yukinori Ozaki, Fumikata Hara, et al.
The Journal of Dermatology|January 12, 2024
Troponin-guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor-related myocarditisRino Toyoshima, Jiro Uehara, Yurie Matsuzaki, et al.
Cancer Science|December 24, 2017
Tumor-associated CD204<sup>+</sup> M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinomaAsuka Kawachi, Hiroshi Yoshida, Shigehisa Kitano, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanomaMichael A Postow, Jianda Yuan, Shigehisa Kitano, et al.
International Journal of Hematology|October 7, 2005
Nephrotic syndrome with extensive mesangiolysis as a clinical manifestation of chronic graft-versus-host disease (GVHD)Keiki Kawakami, Yasuyuki Watanabe, Katsumi Mukai, et al.
ESMO Open|April 12, 2020
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trialsYutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, et al.
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
Cancer Immunology, Immunotherapy : CII|September 13, 2021
Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodiesMorinobu Seki, Shigehisa Kitano, Shigeaki Suzuki
Biomed Research International|July 11, 2015
Clinical Development of Immune Checkpoint InhibitorsAyumu Ito, Shunsuke Kondo, Kohei Tada, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 26, 2022
[The Analysis of Tumor Immune Microenvironment in Muscle-Invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy]Daiki Ikarashi, Shigehisa Kitano, Tetsuya Nakatsura, et al.
BMC Cancer|October 31, 2019
Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reportsKoji Yoshino, Takayuki Nakayama, Ayumu Ito, et al.
Lancet (London, England)|July 4, 2021
Pembrolizumab plus chemotherapy in triple-negative breast cancerJun Masuda, Yukinori Ozaki, Fumikata Hara, et al.
The Journal of Dermatology|January 12, 2024
Troponin-guided utilization of methylprednisolone pulse, intravenous immunoglobulin, and mycophenolate mofetil for successful control of immune checkpoint inhibitor-related myocarditisRino Toyoshima, Jiro Uehara, Yurie Matsuzaki, et al.
Cancer Science|December 24, 2017
Tumor-associated CD204<sup>+</sup> M2 macrophages are unfavorable prognostic indicators in uterine cervical adenocarcinomaAsuka Kawachi, Hiroshi Yoshida, Shigehisa Kitano, et al.
Methods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Markers for anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) therapy in melanomaMichael A Postow, Jianda Yuan, Shigehisa Kitano, et al.
International Journal of Hematology|October 7, 2005
Nephrotic syndrome with extensive mesangiolysis as a clinical manifestation of chronic graft-versus-host disease (GVHD)Keiki Kawakami, Yasuyuki Watanabe, Katsumi Mukai, et al.
ESMO Open|April 12, 2020
Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trialsYutaka Fujiwara, Aya Kuchiba, Takafumi Koyama, et al.
Pageof 15